| |
| Device | Edwards SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve system |
| Generic Name | Aortic valve, prosthesis, percutaneously delivered |
| Applicant | Edwards Lifesciences, LLC One Edwards Way Irvine, CA 92614 |
| PMA Number | P140031 |
| Supplement Number | S182 |
| Date Received | 11/15/2024 |
| Decision Date | 04/30/2025 |
| Product Code |
NPT |
| Docket Number | 25M-1145 |
| Notice Date | 05/05/2025 |
| Advisory Committee |
Cardiovascular |
| Clinical Trials | NCT03042104
|
| Supplement Type | Panel Track |
| Supplement Reason | Labeling Change - Indications/instructions/shelf life/tradename |
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement Approval for the Edwards SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve system for expanding the indications to include patients with asymptomatic severe aortic stenosis. This device is indicated to reduce the risks associated with progression from asymptomatic to symptomatic severe native calcific aortic stenosis in patients who are judged by a heart team to be appropriate for transcatheter heart valve replacement therapy. |
| Approval Order | Approval Order |
| Summary | Summary of Safety and Effectiveness |
| Labeling | Labeling Labeling Part 2 |
| Post-Approval Study | Show Report Schedule and Study Progress |